Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intercalated combination of chemotherapy and icotinib followed by icotinib maintenance compared with chemotherapy followed by icotinib maintenance in EGFR mutant patients with advanced Non-Small-Cell lung cancer: a randomized, open-label, prospective study

Trial Profile

Intercalated combination of chemotherapy and icotinib followed by icotinib maintenance compared with chemotherapy followed by icotinib maintenance in EGFR mutant patients with advanced Non-Small-Cell lung cancer: a randomized, open-label, prospective study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Oct 2014 Status changed from not yet recruiting to recruiting, according to Chinese Clinical Trial Register record.
    • 30 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top